Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term sotatercept extension study in pulmonary arterial hypertension
NL-OMON60662Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event, Number of participants who discontinue study treatment due to an adverse event and 6 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON60662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60662.